My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
    Retrovirology. 2009 Mar 5;6:25.

    Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

    Serrao E, Odde S, Ramkumar K, Neamati N.

    Source

    Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los Angeles, CA 90089, USA. eserrao@usc.edu

    Erratum in

    • Retrovirology. 2009;6:33.

    Abstract

    Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions with the protein. Resulting me-too drugs have shown favorable pharmacokinetic properties and appear drug-like but, as expected, most have a highly similar interaction with IN to that of raltegravir. We propose that, based upon conclusions drawn from our docking studies illustrated herein, most of these me-too MK-0518 analogues may experience a low success rate against raltegravir-resistant HIV strains. As HIV has a very high mutational competence, the development of drugs with new mechanisms of inhibitory action and/or new active substituents may be a more successful route to take in the development of second- and third-generation IN inhibitors.

    PMID:
    19265512
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2660292
    Free PMC Article

    Images from this publication.See all images (8) Free text

    Figure 7
    Figure 4
    Figure 3
    Figure 6
    Figure 5
    Figure 1
    Figure 2
    Figure 8

    Publication Types, MeSH Terms, Substances

    Publication Types

    MeSH Terms

    Substances

    LinkOut - more resources

    Full Text Sources

    Other Literature Sources

    Libraries

      Supplemental Content

      Click here to read Click here to read

      Related citations

      See reviews... See all...

      Cited by 8 PubMed Central articles

      See all...

      Chemical compound information

      • Chemical compound molecule image MK 0518
        MW: 444.41 g/mol
        MF: C20H21FN6O5
      See 10 citations for this compound....

      Related information

      • Related Citations
        Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
      • Compound (MeSH Keyword)
        PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
      • References for this PMC Article
        Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
      • Substance (MeSH Keyword)
        PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
      • Free in PMC
        Free full text articles in PMC
      • Cited in PMC
        Full-text articles in the PubMed Central Database that cite the current articles.

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk